載入...
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Abstract Background Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician’s global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also,...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMC
2017-07-01
|
| 叢編: | Allergy, Asthma & Clinical Immunology |
| 主題: | |
| 在線閱讀: | http://link.springer.com/article/10.1186/s13223-017-0206-9 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|